Aktienanalyse zu Vericel Corp (VCEL)VCELVericel Corp

Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vericel Corp (VCEL) is a good buy right now due to its strong financial performance, including a gross margin of 72.82% in Q2 2026 and a recent analyst price target of $58, which suggests a potential upside of 44.6% from the current price of $40.13. Additionally, the company has raised its 2026 revenue guidance to $330 million to $340 million, reflecting confidence in future growth. However, the main risk is the high forward P/E ratio of 57.14, indicating that the stock may be overvalued if growth expectations are not met.

4 analysts cover VCEL: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 57.67.